Neuromodulation & brain health.
Magnetic, electrical, acoustic and light stimulation of the brain, graded by evidence. What it can treat, where it fits in healthy aging, and where the data stop.
A tool for specific conditions, not an anti-aging device
Brain aging is shaped mostly by blood pressure, cholesterol, glucose, hearing, sleep, mood, activity and social life. The 2024 Lancet Commission links nearly half of dementia cases to 14 modifiable risk factors. Those come first.
Neuromodulation treats conditions that wear down brain function in later life: depression, chronic pain, post-viral cognitive symptoms and, in early trials, Alzheimer's disease. No trial shows that stimulating a healthy brain slows aging.
- 01
Foundations
Treat vascular and metabolic risk, hearing and vision; move, sleep, stay connected. Brain aging & cognitive reserve
- 02
Diagnosis before devices
New memory or mood symptoms need a work-up for reversible causes and a measured baseline.
- 03
Targeted add-on
Where a diagnosis fits the evidence, rTMS, TPS or other modalities as an add-on, with outcomes re-measured.
What each technique can honestly claim
Grades describe the best-supported use. The brain-aging column says what is known for aging, which is almost always less.
| Modality | Best-supported use | Brain aging | Read more |
|---|---|---|---|
| rTMS Magnetic pulses induce currents in a targeted cortical region. | Established for depression | Brain aging: Alzheimer’s: one positive phase 2 RCT (precuneus). Emerging. | Read the evidence on rTMS |
| TPS Ultrashort acoustic pressure pulses, MRI-navigated. Not focused ultrasound. | Emerging | Brain aging: CE-marked for Alzheimer’s in the EU; sham-controlled RCT missed its primary endpoint. | Read the evidence on TPS |
| tDCS Weak direct current shifts cortical excitability. | Moderate for depression | Brain aging: Cognitive effects in healthy aging are inconsistent. | |
| Gamma tACS / 40 Hz Rhythmic stimulation at 40 Hz, electrical or light-and-sound. | Mouse data · human pilots | Brain aging: Amyloid effects shown in mice; small human pilots in Alzheimer’s. | Read the evidence on Gamma tACS / 40 Hz |
| VNS / taVNS Vagus nerve stimulation, implanted or through the ear. | Established (implanted) · Emerging (taVNS) | Brain aging: taVNS studied for inflammation and long COVID; no aging trials. | Read the evidence on VNS / taVNS |
| Neurofeedback Real-time EEG feedback to train brain-activity patterns. | Moderate for ADHD (debated) | Brain aging: No aging-specific trials. | Read the evidence on Neurofeedback |
| Photobiomodulation Near-infrared light aimed at mitochondrial metabolism. | Emerging | Brain aging: Extensive preclinical data; small early human trials. | Read the evidence on Photobiomodulation |
| CES Microcurrent through ear-clip electrodes. | Low-to-moderate certainty | Brain aging: US clearance for anxiety and insomnia; no aging relevance shown. |
Six reads in a sensible order
- 01 Brain Aging and Cognitive Reserve: What Is Established, What Is Emerging What protects the aging brain? Risk factors and lifestyle trials vs zoster-vaccine signals and neuromodulation, each graded by strength of evidence.
- 02 Transcranial Pulse Stimulation (TPS): What the Evidence Shows TPS is CE-marked for Alzheimer's in the EU, but its 2025 sham-controlled RCT missed its primary endpoint. How it works, what trials show, who it suits.
- 03 What Is TMS? Transcranial Magnetic Stimulation Explained Transcranial magnetic stimulation explained by a physician. TMS vs TPS, FDA clearance, session protocols, and why I rank TPS as the top neuromodulation tool in my practice.
- 04 Vagus Nerve Stimulation: How to Activate Your Body's Calm System Vagus nerve stimulation benefits explained by a physician. Invasive vs non-invasive VNS, cold exposure, HRV measurement, and clinical evidence for inflammation and depression.
- 05 qEEG Brain Mapping: What It Shows and Who Needs It Complete guide to quantitative EEG brain mapping. What the test measures, how it identifies brain dysregulation, and why it matters for neurofeedback and brain fog treatment.
- 06 Transcranial Photobiomodulation: Light Through the Skull Evidence-based review of transcranial photobiomodulation for brain health. Wavelengths, mechanisms, clinical trial data, and what I see in practice.
Douwes Brain Center
Neuromodulation at St. George Hospital is delivered through the Douwes Brain Center, the hospital's brain-health service. Its own site describes the treatments and the clinical process.
Brain Health and Neuromodulation Guide
The physician's guide as a PDF: modalities, evidence grades, safety.
All neuromodulation articles
49 articlesTranscranial Magnetic Stimulation (TMS) 7
- At-Home Brain Stimulation for Depression: ProlivRx and Flow FL-100 — What the 2025–2026 FDA Approvals Mean for Patients
- Accelerated TMS in 2026: SWIFT, 5×5 rTMS, and Faster Routes to Depression Remission
- TMS for Chronic Pain: rTMS Protocols, Evidence, and Patient Selection
- ECT Must Be Banned: A Treatment With No Going Back
- TMS for Anxiety: How Transcranial Magnetic Stimulation Targets GAD, Social Anxiety, and OCD-Spectrum Disorders
- What Is TMS? Transcranial Magnetic Stimulation Explained
- TMS for Depression: What 20 Years of Evidence Shows
Vagus Nerve Stimulation 6
- Vagus Nerve Stimulation for Anxiety: Mechanisms, Techniques, and Clinical Evidence
- Vagus Nerve Stimulation for Rheumatoid Arthritis: Clinical Evidence and Patient Selection
- At-Home Vagus Nerve Exercises: Evidence-Based Techniques
- Vagus Nerve Stimulation for Chronic Fatigue and POTS
- The Vagus Nerve and Inflammation: Cholinergic Anti-Inflammatory Pathway
- Vagus Nerve Stimulation: How to Activate Your Body's Calm System
Neurofeedback 4
PEMF Therapy 6
- PEMF Therapy for Fibromyalgia: Evidence, Protocols, and Clinical Experience
- PEMF Frequency Guide: Which Hz Settings Treat Which Conditions
- PEMF for Lyme Disease and Chronic Pain
- PEMF Therapy Side Effects: What to Expect
- PEMF vs TENS vs Red Light: Comparing Energy Therapies
- PEMF Therapy: Pulsed Electromagnetic Fields for Pain and Healing
PEMF for Bone & Joint Health 2
Photobiomodulation 10
- Photobiomodulation for Alzheimer's Disease: Targeting Neuroinflammation and Mitochondrial Failure With Near-Infrared Light
- Photobiomodulation for Wound Healing: Clinical Evidence and Protocols
- Photobiomodulation for Peripheral Neuropathy: Clinical Evidence and Protocol Guide
- Photobiomodulation for Macular Degeneration: LIGHTSITE III Data and What It Means for Patients
- Photobiomodulation and Sleep Quality: Mechanisms, Evidence, and Clinical Protocol
- Photobiomodulation for Depression: What the Clinical Evidence Actually Shows
- Photobiomodulation for Brain Fog: Mitochondrial Rescue
- PBM vs Red Light Therapy: What's the Difference?
- Transcranial Photobiomodulation: Light Through the Skull
- Photobiomodulation: Red and Near-Infrared Light for the Brain
Brain Fog Treatment 4
Brain Aging 2
Cognitive Enhancement 1
Depression Causes 1
Depression Protocols 2
Ketamine Therapy 1
TMS Neuromodulation 1
TMS Therapy 2
Related, from other sections
- CRP and Depression: What Inflammation Testing Reveals Before You Start TMS
- Treatment-Resistant Depression: The Cause-First Workup Before TMS
- Cerebrolysin: What the Stroke and Dementia Trials Actually Show
- Pinealon (EDR): Brain Bioregulator, Evidence and Dosing
- Psoriasis: An Integrative Medicine Protocol
- Ultraviolet Blood Irradiation (UVBI): A Physician's Clinical Protocol Guide
- CDP-Choline (Citicoline): The Physician's Guide to Dosing, Evidence, and Clinical Use
- 5-HTP and Tryptophan: A Physician's Guide to Serotonin Precursors for Sleep, Mood, and Brain Fog
- Hyperbaric Oxygen Therapy for Long COVID: Evidence, Protocol, and What to Expect
- Mitochondrial Dysfunction: Root Causes, Testing, and Evidence-Based Treatment
- The Glymphatic System: How Sleep Cleans Your Brain — And What Happens When It Doesn't
- Rhodiola Rosea: Clinical Evidence for Fatigue, Cortisol, and Cognitive Performance
The physician's guide to neuromodulation
What neuromodulation is
Neuromodulation uses magnetic, electrical, acoustic or light energy to change how specific brain circuits and nerves work. A medication acts on the whole body’s chemistry. Neuromodulation aims at a network: the dorsolateral prefrontal cortex in depression, the precuneus and default mode network in Alzheimer’s disease, the vagus nerve in epilepsy. Most techniques are non-invasive, and their effects build up over a course of sessions.
At St. George Hospital, neuromodulation is delivered through the Douwes Brain Center, our brain-health service, and is combined with the hospital’s other programmes for chronic illness, post-viral syndromes and cognitive decline.
Why it belongs in a conversation about healthy aging
Brain aging is driven by vascular health, metabolic health, inflammation, sleep, hearing, mood, activity and social life. The 2024 Lancet Commission estimates that nearly half of dementia cases are linked to 14 modifiable risk factors (Livingston 2024). Those are the foundations, and no device replaces them.
Neuromodulation enters at a different point. It is a tool for treating specific conditions that erode brain function in later life: depression, chronic pain, post-viral cognitive symptoms and, in early trials, Alzheimer’s disease. It is a symptomatic and functional treatment. It is not an anti-aging intervention, and no trial shows that stimulating a healthy brain slows aging. The full argument, with grades, is in brain aging and cognitive reserve.
How to read the grades on this page
- Established: consistent evidence from randomised, sham-controlled trials and regulatory approval or clearance for the indication.
- Moderate: positive randomised trials, but smaller, fewer or less consistent.
- Emerging: early randomised data, pilots or mixed results. Reasonable to discuss as an add-on with informed consent.
- Preliminary: mechanistic or animal data, or uncontrolled case series only.
The modalities
Transcranial magnetic stimulation (TMS / rTMS)
A coil over the scalp produces magnetic pulses that induce electrical currents in the cortex underneath. Repetitive TMS is FDA-cleared for treatment-resistant major depression, and deep TMS for OCD and smoking cessation. In a small double-blind RCT (n=29), an accelerated, MRI-targeted protocol (SAINT/SNT) produced remission in 78.6% of patients with treatment-resistant depression at four weeks, against 13.3% with sham (Cole 2022). The result is striking and the sample is small.
For brain aging, the strongest single trial is in Alzheimer’s disease: 24 weeks of rTMS over the precuneus slowed cognitive and functional decline compared with sham in 50 patients (Koch 2022), a single-centre phase 2 result awaiting replication.
Grade: Established for depression · Emerging for Alzheimer’s disease. Read more: TMS guide · TMS for depression · How rTMS works Douwes Brain Center ↗
Transcranial pulse stimulation (TPS)
TPS delivers single, ultrashort acoustic pressure pulses (about 3 microseconds) to brain regions mapped from the patient’s MRI. It is a shock-wave-type stimulus. It is not low-intensity focused ultrasound, which uses longer wave trains, and it is not magnetic stimulation.
The NEUROLITH TPS system has been CE-marked for Alzheimer’s disease in the EU since 2018; it is not FDA-cleared. The first clinical study, Beisteiner 2020, was an uncontrolled pilot in 35 patients that showed feasibility and pre-to-post improvement (Beisteiner 2020). The first sham-controlled RCT, published in 2025 with 60 patients, did not meet its primary cognitive endpoint (P = .68). Exploratory analyses suggested benefit in patients aged 70 or younger and improvement in depressive symptoms; both need confirmation (Matt 2025).
Grade: Emerging (CE-marked for Alzheimer’s in the EU; RCT evidence mixed). Read more: TPS: what the evidence shows
Transcranial direct current stimulation (tDCS)
A weak direct current (typically 1 to 2 mA) through scalp electrodes shifts cortical excitability. In a fully remote, sham-controlled phase 2 trial, home-based tDCS improved depressive symptoms (Woodham 2025). On 8 December 2025 the FDA approved Flow Neuroscience’s FL-100, a home-use tDCS device for depression (premarket approval P230024). Evidence for cognitive benefit in healthy aging is inconsistent.
Grade: Moderate for depression · Preliminary for cognitive enhancement.
Transcranial alternating current and 40 Hz “gamma” stimulation (tACS, sensory)
Rhythmic stimulation at 40 Hz reduced amyloid and changed microglia in mice (Iaccarino 2016). In people with Alzheimer’s disease, small pilots of gamma tACS and of 40 Hz light-and-sound stimulation reported changes in memory scores, perfusion and atrophy (Benussi 2021; Chan 2022).
Grade: Preclinical → early human pilots (Emerging at best).
Vagus nerve stimulation (VNS and taVNS)
Implanted VNS is FDA-approved for drug-resistant epilepsy and treatment-resistant depression. Transcutaneous auricular VNS (taVNS) stimulates the auricular branch of the vagus through the ear and is being studied for inflammation, long COVID, migraine and mood. Trials are small and protocols vary.
Grade: Established for implanted VNS in epilepsy · Emerging for taVNS. Read more: Vagus nerve stimulation · Vagus nerve and inflammation
Neurofeedback and qEEG
Real-time EEG feedback trains people to change their own brain-activity patterns; quantitative EEG (qEEG) maps those patterns. Results depend heavily on protocol, and effects tend to look smaller in blinded comparisons than in open studies.
Grade: Moderate for ADHD (debated) · Emerging elsewhere. Read more: qEEG brain mapping · Neurofeedback vs biofeedback
Transcranial photobiomodulation (PBM)
Near-infrared light absorbed by mitochondrial cytochrome c oxidase is proposed to improve cellular energy metabolism and blood flow. Preclinical data are extensive; controlled human trials are small and early.
Grade: Emerging. Read more: Transcranial photobiomodulation
Pulsed electromagnetic field therapy (PEMF)
PEMF devices have long been FDA-cleared for non-union fractures. Evidence for pain and other uses is fragmented and of mixed quality.
Grade: Established for bone healing · Mixed elsewhere. Read more: PEMF therapy
Cranial electrotherapy stimulation (CES)
Low-level alternating microcurrent through ear-clip electrodes. In the US, CES devices are cleared for anxiety and insomnia; claims for depression fall under stricter premarket rules. The trials are small and heterogeneous.
Grade: Low-to-moderate certainty (small, heterogeneous trials).
Evidence summary
| Modality | Best-supported use | Brain-aging relevance | Grade |
|---|---|---|---|
| rTMS | Treatment-resistant depression | Precuneus rTMS in Alzheimer’s (one phase 2 RCT) | Established (depression) · Emerging (AD) |
| TPS | Alzheimer’s add-on (CE-marked, EU) | Sham-controlled RCT missed primary endpoint; age ≤70 signal | Emerging |
| tDCS | Depression | Cognitive effects inconsistent | Moderate (depression) |
| Gamma tACS / 40 Hz sensory | None established | Mouse data; human pilots | Emerging at best |
| VNS / taVNS | Epilepsy, TRD (implanted) | taVNS studied for inflammation and long COVID | Established (implanted) · Emerging (taVNS) |
| Neurofeedback | ADHD (debated) | No aging-specific trials | Moderate · Emerging |
| Photobiomodulation | None established | Early human data | Emerging |
| CES | Anxiety, insomnia (US clearance) | None | Low-to-moderate certainty |
How the right modality is chosen
A neuromodulation plan starts with a diagnosis, not a device:
- Clinical assessment and history, including reversible causes of cognitive or mood symptoms (thyroid, B12, medications, sleep apnoea, depression).
- Neurocognitive testing to set a baseline that can be re-measured.
- qEEG or imaging where it changes the decision.
- Matching the modality to the indication and the evidence, then re-measuring after the course so that a non-response is recognised.
Safety and who it is not for
Non-invasive neuromodulation is generally well tolerated. Typical effects are scalp discomfort or headache with TMS and skin irritation under tDCS electrodes. Seizures with TMS are rare and screened for.
Neuromodulation is not for:
- Healthy people seeking anti-aging or enhancement. No trial supports it.
- Anyone with new cognitive symptoms who has not been assessed. Diagnosis comes first.
- People with modality-specific contraindications, for example certain metal or electronic implants near the coil (TMS), skull defects or bleeding risk in the treatment path (TPS), or uncontrolled epilepsy. The treating centre should screen in writing.
The honest bottom line
Neuromodulation is one of the most interesting areas of brain medicine, and some of it is established care. For brain aging specifically, the evidence is early: one positive phase 2 trial for rTMS in Alzheimer’s disease, one sham-controlled TPS trial that missed its primary endpoint, and pilots for gamma stimulation. That is enough to offer some of these treatments as add-ons with clear informed consent. It is not enough to sell them as a way to keep a healthy brain young.
For a broader overview of the techniques, the Douwes Brain Center maintains a guide to non-invasive neuromodulation Douwes Brain Center ↗.
References
- Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024. PMID: 39096926
- Cole EJ, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022. PMID: 34711062
- Koch G, et al. Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial. Brain. 2022. PMID: 36281767
- Beisteiner R, et al. Transcranial pulse stimulation with ultrasound in Alzheimer’s disease: a new navigated focal brain therapy. Adv Sci (Weinh). 2020. PMID: 32042569
- Matt E, et al. Ultrasound neuromodulation with transcranial pulse stimulation in Alzheimer disease: a randomized clinical trial. JAMA Netw Open. 2025. PMID: 40009384
- Woodham RD, et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nat Med. 2025. PMID: 39433921
- Iaccarino HF, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016. PMID: 27929004
- Benussi A, et al. Exposure to gamma tACS in Alzheimer’s disease: a randomized, double-blind, sham-controlled, crossover, pilot study. Brain Stimul. 2021. PMID: 33762220
- Chan D, et al. Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: results of feasibility and pilot studies. PLoS One. 2022. PMID: 36454969
New brain-health research, graded honestly
Email only, no medical details needed. Privacy policy.